Based on the DaVita HealthCare Partners Inc stock forecast from 2 analysts, the average analyst target price for DaVita HealthCare Partners Inc is USD 159.50 over the next 12 months. DaVita HealthCare Partners Inc’s average analyst rating is Hold . Stock Target Advisor’s own stock analysis of DaVita HealthCare Partners Inc is Slightly Bullish , which is based on 7 positive signals and 4 negative signals. At the last closing, DaVita HealthCare Partners Inc’s stock price was USD 141.50. DaVita HealthCare Partners Inc’s stock price has changed by -7.43% over the past week, -1.36% over the past month and +9.03% over the last year.
Past 12 monthsNext 12 months
No recent analyst target price found for DaVita HealthCare Partners Inc
No recent average analyst rating found for DaVita HealthCare Partners Inc
Company Overview DaVita HealthCare Partners Inc
DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In addition, the company offers integrated care and disease management services to patients in risk-based and other integrated care arrangements; clinical research programs; physician services; and comprehensive kidney care services. Further, it engages in the provision of inpatient dialysis services and related laboratory services; and transplant software business. The company was formerly known as DaVita HealthCare Partners Inc. and changed its name to DaVita Inc. in September 2016. DaVita Inc. was incorporated in 1994 and is headquartered in Denver, Colorado. Read Less
DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and...Read More
Frequently Asked Questions About DaVita HealthCare Partners Inc (DVA) Stock
Based on ratings from 2 analysts DaVita HealthCare Partners Inc's stock is Hold . Stock Target Advisor's fundamental analysis is Slightly Bullish . The stock has buy, sell and 2 hold ratings.
Unfortunately we do not have enough data on DVA's stock to indicate if its a good dividend stock.
Based on targets from 2 analysts, the average taret price for DVA is USD 159.50 over the next 12 months. The maximum analyst target price is USD 169 while the minimum anlayst target price is USD 150.
DVA stock's Price/Earning ratio is 13.88.
Our analysis grades DVA stock's Price / Earning ratio at F. This means that DVA stock's Price/Earning ratio is above 41% of the stocks in the Medical Care Facilities sector in the NYE exchange.
Based on this DVA may be fairly valued for its sector
The last closing price of DVA's stock was USD 141.50.
The most recent market capitalization for DVA is USD 11.92B.
Based on targets from 2 analysts, the average taret price for DVA is projected at USD 159.50 over the next 12 months.
This means that DVA's stock price may go up by +12.72% over the next 12 months.
We can't find any ETFs which contains DaVita HealthCare Partners Inc's stock.
As per our most recent records DaVita HealthCare Partners Inc has 76,000 Employees.
DaVita HealthCare Partners Inc's registered address is 2000 16th Street, Denver, CO, United States, 80202.
You can get more information about it from DaVita HealthCare Partners Inc's website at https://www.davita.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior capital utilization
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Highly leveraged
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
Frequently Asked Questions About DaVita HealthCare Partners Inc (DVA) Stock
Based on ratings from 2 analysts DaVita HealthCare Partners Inc's stock is Hold . Stock Target Advisor's fundamental analysis is Slightly Bullish . The stock has buy, sell and 2 hold ratings.
Unfortunately we do not have enough data on DVA's stock to indicate if its a good dividend stock.
Based on targets from 2 analysts, the average taret price for DVA is USD 159.50 over the next 12 months. The maximum analyst target price is USD 169 while the minimum anlayst target price is USD 150.
DVA stock's Price/Earning ratio is 13.88.
Our analysis grades DVA stock's Price / Earning ratio at F. This means that DVA stock's Price/Earning ratio is above 41% of the stocks in the Medical Care Facilities sector in the NYE exchange.
Based on this DVA may be fairly valued for its sector
The last closing price of DVA's stock was USD 141.50.
The most recent market capitalization for DVA is USD 11.92B.
Based on targets from 2 analysts, the average taret price for DVA is projected at USD 159.50 over the next 12 months.
This means that DVA's stock price may go up by +12.72% over the next 12 months.
We can't find any ETFs which contains DaVita HealthCare Partners Inc's stock.
As per our most recent records DaVita HealthCare Partners Inc has 76,000 Employees.
DaVita HealthCare Partners Inc's registered address is 2000 16th Street, Denver, CO, United States, 80202.
You can get more information about it from DaVita HealthCare Partners Inc's website at https://www.davita.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for DVA !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
